Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Cognitive Function
A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline
This study is testing whether a special type of brain radiation that avoids the hippocampus can help people with brain tumors keep their thinking skills better than regular radiation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 84 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT02504788 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of hippocampal-sparing whole brain radiotherapy (WBRT) on neurocognitive function decline in patients with brain metastases. It aims to determine whether avoiding radiation exposure to the hippocampus can mitigate cognitive decline associated with WBRT. Patients with confirmed non-hematopoietic malignancies and limited brain metastases will be treated with this specialized radiotherapy approach. The study will assess cognitive outcomes compared to traditional WBRT methods.
Who should consider this trial
Good fit: Ideal candidates are patients with non-hematopoietic malignancies and limited brain metastases who are referred for WBRT.
Not a fit: Patients with metastases located near the hippocampus or those with a history of prior brain radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could help preserve cognitive function in patients undergoing treatment for brain metastases.
How similar studies have performed: While there is ongoing research in hippocampal-sparing techniques, this specific approach is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for therapeutic or prophylactic WBRT * Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 % * The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 4 cm Exclusion Criteria: * Patients with MRI-identified metastasis within 5 mm perihippocampally * Clinical suspicion of leptomeningeal spreading * History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons
Where this trial is running
Taoyuan
- Chang Gung Memorial Hospital — Taoyuan, Taiwan (Recruiting)
Study contacts
- Study coordinator: Chi-Cheng Chuang, M.D.
- Email: ccc2915@cgmh.org.tw
- Phone: +886-33281200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.